Cargando…

Monthly Cost-Sharing Limits and Out-of-pocket Costs for Commercially Insured Patients in the US

This cross-sectional study assesses how much monthly cost-sharing limits, as opposed to annual limits, could reduce out-of-pocket costs for commercially insured patients in the US.

Detalles Bibliográficos
Autores principales:	Shafer, Paul R., Horný, Michal, Dusetzina, Stacie B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478767/ https://www.ncbi.nlm.nih.gov/pubmed/36107430 http://dx.doi.org/10.1001/jamanetworkopen.2022.33006

Ejemplares similares

Concordance of Disclosed Hospital Prices With Total Reimbursements for Hospital-Based Care Among Commercially Insured Patients in the US
por: Horný, Michal, et al.
Publicado: (2021)

Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products
por: Gupta, Arjun, et al.
Publicado: (2022)

Out-of-Pocket Costs for Colonoscopy After Noninvasive Colorectal Cancer Screening Among US Adults With Commercial and Medicare Insurance
por: Fendrick, A. Mark, et al.
Publicado: (2021)

Out-of-Pocket Costs and Prescription Filling Behavior of Commercially Insured Individuals With Chronic Obstructive Pulmonary Disease
por: Patel, Bhavin, et al.
Publicado: (2022)

Trends in Well-Child Visits With Out-of-Pocket Costs in the US Before and After the Affordable Care Act
por: Shafer, Paul R., et al.
Publicado: (2021)

Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018
por: Yeung, Kai, et al.
Publicado: (2021)

Out-of-Pocket Costs for Colposcopy Among Commercially Insured Women From 2006 to 2019
por: Fendrick, A. Mark, et al.
Publicado: (2022)

Out-of-Pocket Costs of Treatment Among Employer-Insured Women With Invasive Breast Cancer
por: Hager, Audrey, et al.
Publicado: (2023)

Out-of-Pocket Costs of Diagnostic Breast Imaging Services After Screening Mammography Among Commercially Insured Women From 2010 to 2017
por: Lowry, Kathryn P., et al.
Publicado: (2021)

Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit
por: Rotenstein, Lisa S., et al.
Publicado: (2018)

Access to High-Cost Medications After a Cap on Monthly Out-of-Pocket Spending in California
por: Taylor, Erin Audrey, et al.
Publicado: (2021)

Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018
por: Alpern, Jonathan D., et al.
Publicado: (2022)

Changes in Out-of-Pocket Costs for US Hospital Admissions Between December and January Every Year
por: Kannan, Sneha, et al.
Publicado: (2023)

Trends in Out-of-Pocket Cost of Glucagon, 2010-2020
por: Zupa, Margaret, et al.
Publicado: (2022)

Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019
por: Erath, Alexandra, et al.
Publicado: (2020)

Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps
por: Dusetzina, Stacie B., et al.
Publicado: (2021)

Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults
por: Nabi, Junaid, et al.
Publicado: (2020)

Spending and Out-of-Pocket Prices for Brand-Name Drugs Among Commercially Insured Individuals in Massachusetts, 2015-2017
por: Aaron, Micah B., et al.
Publicado: (2021)

Potential Change in Insulin Out-of-Pocket Spending Under Cost-Sharing Caps Among Pediatric Patients With Type 1 Diabetes
por: Chua, Kao-Ping, et al.
Publicado: (2020)

Ambulatory Health Care Service Use and Costs Among Commercially Insured US Adults With Congenital Heart Disease
por: Agarwal, Anushree, et al.
Publicado: (2020)

Evaluating Costs Associated With Genetic Counseling Among Commercially Insured US Patients With Cancer From 2013 to 2019
por: Roberson, Mya L., et al.
Publicado: (2022)

Costs of pediatric liver transplantation among commercially insured and Medicaid-insured patients with cholestasis in the US
por: Miloh, Tamir, et al.
Publicado: (2023)

Out of Pocket Costs and Variation in Panniculectomy Procedures
por: Oleru, Olachi, et al.
Publicado: (2023)

Estimating the Cancer Treatment Cost for 5 Common Types of Cancer with Separating Out-of-Pocket and Governmental Costs in Afghanistan, 2020
por: Abdullah, Maihan, et al.
Publicado: (2023)

Cost of Treatment in a US Commercially Insured, HIV-1–Infected Population
por: Solem, Caitlyn T., et al.
Publicado: (2014)

Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018
por: Peet, Evan D., et al.
Publicado: (2022)

Discussing Out‐of‐Pocket Costs With Patients: Shared Decision Making for Sacubitril‐Valsartan in Heart Failure
por: Smith, Graham H., et al.
Publicado: (2018)

Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
por: Tseng, Chien-Wen, et al.
Publicado: (2020)

Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use
por: Auty, Samantha G., et al.
Publicado: (2021)

16. Attributable Mortality, Healthcare Costs and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2021)

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population
por: Wang, Ching-Yu, et al.
Publicado: (2022)

Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022
por: Dusetzina, Stacie B., et al.
Publicado: (2023)

Colorectal cancer screening use among insured adults: Is out-of-pocket cost a barrier to routine screening?
por: Perisetti, Abhilash, et al.
Publicado: (2018)

Costs of Severe Maternal Morbidity in U.S. Commercially Insured and Medicaid Populations: An Updated Analysis
por: Black, Christopher M., et al.
Publicado: (2021)

Association of Out-of-Pocket Pharmacy Costs with Adherence to Varenicline
por: Suehs, Brandon T., et al.
Publicado: (2014)

Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence
por: Galaznik, Aaron, et al.
Publicado: (2014)

Are patients willing to incur out of pocket costs for pharmacogenomic testing?
por: Bielinski, Suzette J., et al.
Publicado: (2016)

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
por: Aggarwal, Rahul, et al.
Publicado: (2021)

Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma
por: Jazowski, Shelley A., et al.
Publicado: (2022)

Changes in out-of-pocket costs for hormonal IUDs after implementation of the Affordable Care Act: an analysis of insurance benefit inquiries
por: Bearak, Jonathan M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_umt1so6h2q55osumc3mldjd6di